Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Theravance Biopharma, Inc. (TBPH) had Return on Tangible Equity of 35.69% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$107.46M |
|
$105.89M |
|
-- |
|
$107.46M |
|
$111.07M |
|
$-3.60M |
|
$132.85M |
|
$129.25M |
|
$54.11M |
|
$105.89M |
|
$105.89M |
|
$105.89M |
|
$17.18M |
|
$-3.60M |
|
$-4.81M |
|
50.32M |
|
51.51M |
|
$2.10 |
|
$2.06 |
|
| Balance Sheet Financials | |
$418.46M |
|
$5.89M |
|
$67.11M |
|
$485.57M |
|
$38.30M |
|
-- |
|
$150.54M |
|
$188.85M |
|
$296.72M |
|
$296.72M |
|
$296.72M |
|
51.07M |
|
| Cash Flow Statement Financials | |
$238.54M |
|
$-105.28M |
|
$-3.25M |
|
$38.63M |
|
$168.64M |
|
$130.01M |
|
$18.48M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-3.35% |
|
-3.35% |
|
-4.47% |
|
120.27% |
|
98.54% |
|
$238.50M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
-- |
|
1.12 |
|
324.50 |
|
35.69% |
|
|
Return on Tangible Equity |
35.69% |
21.81% |
|
35.69% |
|
$5.81 |
|
$4.63 |
|
$4.63 |
|